Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction

Negative Inotropy of the Gastric Proton Pump Inhibitor Pantoprazole in Myocardium From Humans and Rabbits

“…1 The same holds true for patients with severe liver impairment. 28 Recent American 29 and Canadian 30 studies have shown that appropriate use of intravenous PPIs was seen in less than half of the patients. In view of our data, PPIs should be prescribed carefully.…”

Genetics of Response to Proton Pump Inhibitor Therapy

“…In Patients with impaired hepatic function often require gastric the previously cited study, [72] eradication therapy initially included acid suppressant therapy but are at increased risk for drug interac20mg of rabeprazole with significant differences in cure rate tions and may require dosage adjustments. Ferron et al [78] investiamongst the three CYP2C19 genotypes. With retreatment using gated the pharmacokinetics and tolerability of pantoprazole in rabeprazole 40mg, eradication failed in only one patient.…”

“…At present, however, One study that does provide conflicting data is reported by data are emerging regarding dose adjustment for PPIs with respect Hokari et al [73] A total of 102 H. pylori-positive patients with to CYP2C19 genotype, which may involve dose reduction for gastric ulcer were randomly allocated to three groups: rabeprazole PMs. Therefore, Ferron et al [78] are correct in advising that caution 10mg (RAC10), rabeprazole 20mg (RAC20), or rabeprazole 40mg should be exercised when administering pantoprazole to patients (RAC40) plus amoxicillin 750mg and clarithromycin 200mg twice with severe hepatic impairment. daily for 7 days.…”

Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters

“…Treatment of HIV-infected patients with HIV-1 protease inhibitors (PIs) as part of highly active antiretroviral therapy (HAART) has contributed considerable reductions in HIV viral load and increased in CD 4 lymphocyte numbers, thereby slowing disease progression and improving patient survival. However, despite this clinical success, it is recognized that PI-based therapy is correlated with a number of significant metabolic complications, including lipodystrophy, hyperlipidaemia, and insulin resistance.…”

“…The presence of liver dysfunction that leads to increased plasma drug or metabolite concentrations may increase the prospect of toxicity which results in more complex drug-drug interaction. Hence, the preferred approach to prescribing medications for hepatic impaired patients is to select drugs that have predictable pharmacokinetic properties, are minimally affected by hepatic impairment and have a low potential for drug interactions with other drugs [4]. Safe pharmacological treatment of these complications requires an understanding of the drug-drug interactions between antiretroviral drugs and the drugs used in the treatment of diabetes [5].…”